Background: Antenatal magnesium sulfate can potentially reduce the risk of cerebral palsy
in neonates delivered between 24 and 32 weeks of gestational age. Some studies using …

In women at risk of early preterm imminent birth, from viability to 30 weeks of gestation, use
of MgSO4 for neuroprotection of the fetus is recommended. In pregnancies below 32–34 …

OBJECTIVE: To evaluate the association of duration of magnesium sulfate infusion with
stillbirth or death, cerebral palsy, and select adverse maternal and neonatal outcomes …

Please cite this paper as: Huusom L, Secher N, Pryds O, Whitfield K, Gluud C, Brok J.
Antenatal magnesium sulphate may prevent cerebral palsy in preterm infants—but are we …

Background: Antenatal magnesium in preterm labor for neuroprotection decreases the
incidence of cerebral palsy. However, there are no guidelines on the dose and duration of …

The aim of the study was to identify the optimal therapeutic maternal magnesium drug
exposure and maternal serum concentration to prevent cerebral palsy in the extremely …

OBJECTIVE: Clinical trials support the efficacy and safety of magnesium sulfate for cerebral
palsy prevention. We evaluated the implementation of a clinical protocol for the use of …

Prevention of neurologic disability associated with preterm birth is one of the major
challenges in current perinatal medicine. Magnesium sulfate (MgSO4), the focus of this …

Preterm delivery (PTD) is a major cause of neonatal morbidity and mortality, with surviving
infants at risk for long-term neurologic sequelae. Although any birth occurring before the …

The use of magnesium for prevention of cerebral palsy in preterm infants has been a
pressing clinical question for some time. This issue was recently brought to the forefront …